Radotinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Radotinib，有时也称为其研究名称 IY5511。

Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors.

——

——

IY-5511

Tyrosine Kinase

Bcr-Abl

Bcr-Abl1

Cancer

——

926037-48-1

530.5

C27H21F3N8O

>98% (HPLC)

DMSO: 10 mM

CC1=CN(C=N1)C1=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=NC=CN=C3)=C(C)C=C2)=CC(=C1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years